Amarin Corporation plc this week announced that its poster presentation on Vascepa will be displayed at the American Diabetes Association Scientific Session.
The new data resulted from an analysis of the Type 2
diabetes participants who continue to have persistent high triglyceride levels.
Participants in the 12-week Phase III trial were at high risk for developing cardiovascular disease. Even after stable statin therapy, the participants continued to have triglyceride levels between 200 mg/dL and 500 mg/dL.
The ANCHOR trial evaluated the effectiveness of Vascepa in helping reduce triglycerides in participants with Type 2 diabetes. The U.S. Food and Drug Administration (FDA) approved Vascepa in 2012 as a prescription diet supplement used in conjunction with a low-fat, low cholesterol diet to reduce triglycerides in the blood.
While Vascepa is an omega-3 fatty acid supplement, it is not fish oil. Each capsule contains 1 gram of a single molecule active ingredient, which is isolated from fish. The manufacturing process is monitored by the FDA to ensure that the product contains only the molecule and no impurities.
Before prescribing Vascepa, health providers should make sure the patient is not allergic to fish or shellfish. Sensitive individuals can have an anaphylactic reaction to the supplement.
Alerts Sign-up